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1352Objectives: Continuous flow left ventricular assist devices are used in end-stage systolic heart failure. However,
about one half of the patients with heart failure exhibit diastolic dysfunction with a normal ejection fraction. In
the present study, the possible hemodynamic consequences of continuous flow left ventricular assist devices use
for these patients were investigated.
Methods:A previously developed cardiovascular model was modified to reproduce the peculiar hemodynamics
of heart failure with a normal ejection fraction. The model was based on and validated with patient data derived
from the published data. A continuous flow left ventricular assist device model was included and the hemody-
namic effects of pump support evaluated at rest and during exercise.
Results: The model accurately reproduced the published data both at rest and during exercise, leading to sim-
ulated hemodynamic values within the standard deviations of patient variability. At rest, pump support decreased
the end-diastolic left ventricular pressure (6 vs 15 mm Hg) and volume (88 vs 135 mL). During exercise, max-
imal pump support substantially unloaded the left ventricle (end-diastolic pressure, 14 vs 35 mm Hg; volume,
133 vs 158 mL) and the pulmonary venous circulation (left atrial pressure, 12 vs 24 mm Hg) and resulted in
a slight increase in cardiac output (11.7 vs 9.9 L/min).
Conclusions: The simulation results suggested that continuous flow left ventricular assist devices improve the
hemodynamics in patients with heart failure and a normal ejection fraction. For an optimal use of continuous
flow left ventricular assist devices, low speeds should be maintained at rest, to avoid suction. However, during
physical activity, higher speeds are needed to prevent an abnormal increase in the ventricular filling pressures typ-
ical of patients with heart failure and a normal ejection fraction. (J Thorac Cardiovasc Surg 2013;145:1352-8)The use of a continuous flow left ventricular (LV) assist de-
vice (CF-LVAD) has recently become the standard treat-
ment of patients with end-stage heart failure, with
tremendous improvement in mortality and morbidity.1,2
Typically, CF-LVADs are implanted in patients with dilated
or ischemic cardiomyopathy, characterized by severe LV
systolic dysfunction with reduced ejection fraction. For
example, in the study by Slaughter and colleagues,1
a CF-LVADwas implanted in 134 patients with heart failure
with a preimplant LV ejection fraction of 17%  5.5%.
However, in the past 2 decades, epidemiologic studies
have shown that about one half of the patient population
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The Journal of Thoracic and Cardiovascular Surespecially the elderly and women, have a normal ejection
fraction (ejection fraction, 50%). This condition is usu-
ally termed ‘‘heart failure with a normal ejection fraction’’
(HFNEF).3,4 Patients with HFNEF are characterized by an
alteration of the LV diastolic function with prolonged
relaxation and reduced ventricular compliance. These
alterations lead to an elevated LV diastolic pressure,
a blunted diastolic function reserve with a small increase
in the end-diastolic volume, despite a marked increase in
ventricular filling pressures, a depressed chronotropic re-
serve, and exercise intolerance.4 Unfortunately, current
therapeutic treatment strategies for patients with HFNEF
have not increased the survival rates.3,4 Patients with
HFNEF are not yet necessarily considered for CF-LVAD
implantation and when disease progresses to end-stage
heart failure, they have a poor prognosis, with heart trans-
plantation the only curative treatment option.
Since CF-LVADs have proved their ability to fully restore
body perfusion and to unload the failing left ventricle and
the pulmonary circulation in the past 10 years,1,5 it seems
reasonable to investigate whether patients with HFNEF
could also benefit from mechanical assistance. We, thus,
hypothesized that CF-LVADs can facilitate ventricular fill-
ing, which is otherwise compromised in these patients, and,
consequently, unload the pulmonary circulation. Thisgery c May 2013
Abbreviations and Acronyms
CF-
LVAD
¼ continuous flow left ventricular assist
device
EDP ¼ end-diastolic pressure
EDV ¼ end-diastolic volume
EDPVR ¼ end-diastolic pressure–volume
relationship
HFNEF ¼ heart failure with a normal ejection
fraction
LAP ¼ left arterial pressure
LV ¼ left ventricular
NYHA ¼ New York Heart Association
Moscato et al Evolving Technology/Basic Sciencewould thus represent a potential option for symptom reduc-
tion and improved exercise tolerance. In the present study,
the unloading effects of a CF-LVAD were evaluated in
a computer simulation of the hemodynamics of HFNEF
patients and compared with an unassisted case, both at
rest and during physical activity.E
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We describe the computer model of the cardiovascular system, adapted
to reproduce the hemodynamics observed in patients with HFNEF and of
a centrifugal CF-LVAD. Additionally, the published data used for compar-
ison and validation of the simulation results are presented. Finally, the sim-
ulation of the HFNEF model, including the CF-LVAD, is described, along
with the key questions and hypotheses addressed by the simulation.
Hemodynamic Model of HFNEF and Cardiovascular
Response to Exercise
A previously developed numeric model of the cardiovascular system6,7
has beenmodified to reproduce the peculiar hemodynamics of patients with
HFNEF both at rest and during physical activity. The model was
implemented using Matlab-Simulink (The MathWorks Inc, Natick,
Mass) and comprised a hydraulic closed loop with active atria and ventri-
cles, systemic and pulmonary circulation, and autonomic control mecha-
nisms. A schematic diagram of the model structure is shown in Figure 1.
The modifications to the previous model are briefly discussed: these con-
sisted of the adaptation of the ventricular end-diastolic, end-systolic, and
relaxation properties to patients with HFNEF and in the implementation
of the hemodynamic response to exercise of these patients.
The LVend-diastolic pressure–volume relationship (EDPVR) was mod-
eled with an exponential function.8 The LV end-systolic pressure–volume
relationship was modeled as the sum of the EDPVR and a parabolic func-
tion.9 The normalized elastance function has been simplified to a biexpo-
nential function, which allowed the straightforward adjustment of the
time constant of ventricular pressure relaxation. The parameters of the ven-
tricular EDPVR, and normalized elastance function were chosen to repro-
duce the end-diastolic pressures and volumes and the time course of LV
pressures as reported in previous studies.10-13
The cardiovascular response to exercise was modeled as the interaction
between the central command, which modulates parasympathetic with-
drawal and sympathetic activation by way of a reset of the arterial barore-
flex operating point, and the mechanosensitive and metabolically sensitive
skeletal muscle afferents, which regulate peripheral vasodilatation.14 In the
present model, these mechanisms were implemented at the onset of exer-
cise by an increase of the pressure set point for the baroreflex of 30%The Journal of Thoracic and Carfrom the initial value of 110 mmHg (central command action) and by a de-
crease of the peripheral resistance of 50% from the initial value of 1.04mm
Hg$s/mL (mechanosensitive and metabolically sensitive skeletal muscle
afferents action). The apparent hypotension caused by the set point increase
and the peripheral resistance decrease led to a baroreflex-mediated increase
of the heart rate and contractility to a reduction of the systemic venous un-
stressed volume and systemic vascular constriction. This latter effect, how-
ever, combined with the skeletal muscle afferent vasodilatation, resulted in
a net vasodilatation in the model. The baroreflex systemwasmodeled using
the structure described by Ursino and Magosso,15 with parameter values
adapted to match the heart rate, mean arterial pressure, cardiac output
(CO), and peripheral resistance response of patients with HFNEF.16,17
Model of CF-LVAD
A computer model of a centrifugal rotary blood pump and its cannulas
were used in the present study. The hydrodynamic model of the CF-LVAD
was derived from mock loop experiments, according to a procedure de-
scribed by Moscato and colleagues.18 The validity of the model covered
the usual clinical working ranges with pump speeds of 1.8 to 4.0 krpm,
pump flow of 0 to 10 L/min, and differential pressure of 0 to 150 mm Hg.
Published Data Used for Model Comparison and
Validation
The model simulation results were compared with the published data of
HFNEF patients. From a PubMed search using the keywords ‘‘heart failure
with normal ejection fraction,’’ 10 studies10-13,16,17,19-22 were selected
because of their similar patient inclusion and exclusion criteria (presence
of heart failure symptoms and ejection fraction>50% and the absence
of heart valve disease, heart rhythm disease, and pulmonary disease) and
patient demographics. The pooled demographics for the 243 patients
included age, 60.4  9.4 years, female gender 56.9%  18.0%, body
mass index 29.7  4.4 kg/m2, New York Heart Association (NYHA)
class II in 61.2%  18.1%, and NYHA class III in 38.8%  16.0%.
The pooled mean and variance were calculated from the hemodynamic
variables reported in the published data, both at rest and during exercise,
and were used for comparison with the simulation results. The
hemodynamic variables, which were given in the published studies as
normalized by body surface area (eg, cardiac index), were converted to
non-normalized values (eg, CO) using the body surface area calculated
with Mosteller’s formula. Thus, the body weight was determined by the
body mass index reported in the studies, and the body height was derived
from averaged age- and gender-matched population data. In 1 study, the he-
modynamic values were given as the median and range12 and in another
study as the median and interquartile range,13 thus requiring an estimation
of the mean and standard deviation before pooling.23
Simulation of CF-LVAD Support in the Case of
HFNEF
The CF-LVAD model was included in the HFNEF cardiovascular
model, and a simulation was performed to investigate the effects of me-
chanical assistance on LV filling. The main hypothesis addressed by the
simulation was that the CF-LVAD will leads to a ventricular filling pres-
sure decrease, just as it does in the case of systolic heart failure support.
In addition, the effectiveness of a constant speed support was investigated
during both rest and exercise conditions. In particular, we investigated
whether a constant speed for rest and exercise would be sufficient to guar-
antee adequate unloading of the heart and the pulmonary venous circula-
tion in both cases. The at rest and exercise conditions were simulated
without pump support and with 3 different pump support settings
(pump speed, 2.5, 3.0, and 3.5 krpm). The key hemodynamic variables,
such as the ventricular filling pressure and volume and CO, were com-
pared for the unsupported condition and pump-supported condition at
the 3 different speeds.diovascular Surgery c Volume 145, Number 5 1353
FIGURE 1. Schematic diagram of the hemodynamic model structure, in-
cluding the systemic and pulmonary circulation, continuous flow left ven-
tricular assist device (CF-LVAD), central command, baroreflex and muscle
mechanoreflex and metabolic reflex. MV, Mitral valve; AoV, aortic valve;
TV, tricuspid valve; PV, pulmonary valve; SVR, systemic vascular resis-
tance; PVR, pulmonary vascular resistance; Vusv, unstressed volume in
the systemic veins; Emax, maximal ventricular elastance; HR, heart rate.
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Figure 2, A and B, show the simulated pressure–volume
loop and EDPVR in the presence of a normal healthy ven-
tricle and HFNEF. The remarkable shift of the EDPVR to-
ward greater pressures at relatively normal volumes can be
observed, reflecting the increased ventricular stiffnessFIGURE 2. Simulation results for the pressure–volume loops for A, a normal c
ulation results for the pressure and flow tracings for C, a normal condition and D
pressure; EDPVR, end-diastolic pressure volume relationship; LAP, left atrial p
1354 The Journal of Thoracic and Cardiovascular Surcharacteristic for patients with HFNEF. Figure 2, C and
D, show the pressure and flow waveforms for healthy and
HFNEF conditions. In the HFNEF condition, a delayed re-
laxation with a prolonged LV pressure time constant can be
noted (t¼ 54 vs 24 ms), as well as a change in the shape of
the transmitral blood flow. The latter is characterized by
a slower E wave deceleration time, reflecting impaired re-
laxation, and an increased contribution to filling of the A
wave, reflecting the compensatory atrial contribution to
the impaired early diastolic filling.
The results of the comparison of the hemodynamic data
calculated from the numeric simulation and published
data are listed in Table 1. The relevant data for this compar-
ison are also shown in the histogram plots of Figure 3. The
simulation was able to reproduce the published data very
well, confirming the ability of the model to represent the pe-
culiar hemodynamics of patients with HFNEF both at rest
and during exercise. In the simulation, the heart rate in-
creased with exercise from 69 to 103 beats/min (published
data, from 71  9 to 103  14 beats/min), the LV end-
diastolic pressure (EDP) increased remarkably from 15 to
35 mm Hg (published data, 18  4 to 34  6 mm Hg),
and the LV end-diastolic volume (EDV) increased from
135 to 158 mL (published data, 143  23 to 158  50
mL). In the simulation, as a result of exercise, the systemic
arterial pressure (SAP) increased from 106 to 125 mm Hg
(published data, 105  14 to 123  14 mm Hg), the leftondition and B, heart failure with normal ejection fraction (HFNEF). Sim-
, heart failure with normal ejection fraction. AoF, Aortic flow; AoP, aortic
ressure; LVP, left ventricular pressure; MVF, mitral valve flow.
gery c May 2013
TABLE 1. Comparison of hemodynamic data derived from pooled published data and from model simulation without CF-LVAD assistance
Variable
At rest Exercise
Published data* (n ¼ 264) Model Published datay (n ¼ 46) Model
HR (beats/min) 71  9 69 103  14 103
CO (L/min) 6.26  0.85 5.68 9.55  1.96 9.92
SV (mL) 87  15 84 92  20 97
EDV (mL) 143  23 135 158  50z 158
ESV (mL) 55  18 51 66  45x 61
EF (%) 65  12 62 58  22 61
EDP (mm Hg) 18  4 15 34  6 35
ESP (mm Hg) 136  17 135 158  17 170
SAP (mm Hg) 105  14 106 123  14 125
SBP (mm Hg) 147  16 140 179  17 171
DBP (mm Hg) 82  18 69 96  23 75
PAP (mm Hg) 19  3 21 41  6 39
PCWP (mm Hg) 15  7 11{ 26  4 24{
RAP (mm Hg) 6  2 4 14  4 6
SVR (mm Hg$s/mL) 1.04  0.21 1.08 0.76  0.26 0.72
PVR (mm Hg$s/mL) 0.10  0.07 0.11 0.08  0.05 0.09
t (ms) 54  8 54 — 54
CO, Cardiac output;DBP, diastolic arterial pressure; EDP, end-diastolic pressure; EDV, end-diastolic volume; EF, ejection fraction; ESP, end-systolic pressure; ESV, end-systolic
volume; HR, heart rate; PAP, pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SBP,
systolic arterial pressure; SV, stroke volume; SVR, systemic vascular resistance; t, time constant of left ventricular pressure relaxation; SAP, systemic arterial pressure. *Pooled
data from Zile and colleagues,10 Penicka and colleagues,11 Westermann and colleagues,12 Kasner and colleagues,13 Maeder and colleauges,16 Borlaug and colleagues,17 Kawa-
guchi and colleagues,19 Drazner and colleagues,20 Baicu and colleagues,21 and Borlaug and colleagues.22 yPooled data from Maeder and colleagues16 and Borlaug and col-
leagues.17 zValues calculated from ESV and SV. xValues calculated from the ESP and ventricular end systolic elastance. {Left atrial pressure used for comparison.
Moscato et al Evolving Technology/Basic Scienceatrial pressure (LAP) increased from 11 to 24 mm Hg (pub-
lished data, pulmonary capillary wedge pressure 15  7 to
26  4 mm Hg), and the CO increased from 5.68 to 9.92
L/min (published data, 6.26  0.85 to 9.55  1.96 L/min).
The relevant hemodynamic changes induced by the
CF-LVAD are shown both at rest and during exercise in
Figure 4. The unsupported condition was compared with
the results obtained with the CF-LVAD running at the 3FIGURE 3. Comparison of the hemodynamic variables calculated from the sim
data are represented by bars for mean values and error bars for standard deviatio
for comparison. CO, Cardiac output; EDP, end-diastolic pressure; EDV, end-dia
terial pressure; SAP, systemic arterial pressure; SVR, systemic vascular resistan
The Journal of Thoracic and Cardifferent speeds. The results for the greatest speed (3.5
krpm) at rest are not shown because the ventricular pressure
decreased toward 0, leading to completely emptied cham-
bers and to a probable occurrence of ventricular or atrial
suction. During exercise, the inclusion of the CF-LVAD in
the HFNEF model compared with the unsupported condi-
tion led to a strong reduction of EDP (14 vs 35 mm Hg),
LAP (12 vs 24 mm Hg), and EDV (133 vs 158 mL),ulation and the pooled published data.10-13,16,17,19-22 The pooled published
ns. xPulmonary capillary wedge pressure from the published data were used
stolic volume; HR, heart rate; LAP, left atrial pressure; PAP, pulmonary ar-
ce.
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FIGURE 4. Hemodynamic changes induced by the continuous flow left ventricular assist device (CF-LVAD) running at 3 different speeds (2.5, 3.0, and 3.5
krpm) at rest and during exercise. Data for the unsupported condition are also shown (indicated as ‘‘no pump’’). #Complete empting of the left ventricular
chamber and possible suction occurring at rest in the 3.5-krpm pump speed setting. During exercise, an increase in cardiac output (CO) and a reduction in
both end-diastolic pressure (EDP) and left atrial pressure (LAP) for increasing pump speeds (black arrows). EDV, End diastolic volume;HR, heart rate; PAP,
pulmonary arterial pressure; SAP, systemic arterial pressure; SVR, systemic vascular resistance.
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Sa reduction of the heart rate mediated by the baroreceptor
reflex (88 vs 103 beats/min), together with a slight increase
in the SAP (133 vs 125 mm Hg) and CO (11.73 vs 9.92
L/min).
DISCUSSION
CF-LVADs have proved in recent years to be a very good
option to bridge patients with end-stage heart disease to
transplantation, with survival rates approaching 70% to
80% in the first 2 years after implantation.1,2 This success
triggered interest about the possible use of CF-LVADs
even in less critical patients as partial support devices.24,25
The patients with HFNEF in the present study can also
be considered as having less critical disease, being
characterized by pronounced exercise intolerance but
almost normal physical performance at rest (NYHA class
II and III). The current treatment of these patients is
aimed predominantly at symptom reduction, with a still-
limited increase in patient survival rates (59% at 2 years
after the heart failure diagnosis).3 To our knowledge, no
systematic use of the CF-LVAD in these patients has been
investigated and reported, but only in patients with
NYHA class IV and a highly reduced ejection fraction.1,2
Obviously, the use of CF-LVADs in less sick patients is con-
ceivable only if the mechanical assistance will prove to be
advantageous compared with conventional treatment.
Smaller and easier-to-implant CF-LVADs could eventually
lead to similar or even better survival rates as those ob-
served in patients with systolic heart failure, leading to an
improvement in the current survival of patients with
HFNEF. Additionally, it can be speculated that mechanical
assistance could cause reverse remodeling or even pathol-
ogy reversal, in the case of patients with HFNEF with1356 The Journal of Thoracic and Cardiovascular Surhypertensive etiology. This consideration is based on the
documented experience of partial regression of hypertrophy
after stenotic aortic valve replacement26; thus, it is imagin-
able that the unloading performed by the CF-LVAD could
contribute to an eventual reverse remodeling of the hyper-
trophic heart. It can also probably be assumed that
CF-LVAD use for HFNEF could reverse the neurohormonal
milieu derangement of heart failure and thus favor
recovery.27
In the present study, however, we investigated the use of
CF-LVAD and its effectiveness only with regard to the
possible hemodynamic benefits for patients with HFNEF.
The results from the simulation (Figure 4) showed that
CF-LVAD assistance could increase the CO compared
with the unassisted condition (CO, 11.73 vs 9.92 L/min)
during physical activity. At the same time, it could also
unload the left ventricle (EDP, 14 vs 35 mm Hg) and de-
crease the pulmonary circulation remarkably (LAP, 12 vs
24 mm Hg). This, altogether, would contribute to alleviate
the symptoms and the marked exercise intolerance typical
for patients with HFNEF, leading to an overall improve-
ment in their quality of life. Similar to the case of CF-
LVAD use in those with systolic heart failure, 1 of the
key benefits of mechanical assistance for diastolic heart
failure is the improved Frank-Starling reserve of the left
ventricle. This allows an increase in CO, which is obtain-
able still at a low LAP and, therefore, pulmonary venous
pressures, similar to the case of support in patients with
systolic heart failure.5 In contrast to the case of CF-
LVADs in systolic heart failure, the present simulation
suggests that in the case of HFNEF, a constant pump speed
for the rest/exercise conditions is not advisable. The sim-
ulation data implied that the pump speed should be keptgery c May 2013
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Slow at rest (owing to the risk of ventricular/atrial suction)
and that speed should be then increased during exercise
for the assistance to be effective in keeping the LAP and
pulmonary pressure low. In particular, it can be observed
in Figure 4 that a speed of 2.5 krpm could be adequate at
rest but completely ineffective during exercise, and a speed
of 3.5 krpm could lead to suction at rest but be adequate dur-
ing exercise. For this reason, a constant speed strategy, such
as is currently used for patients with systolic heart failure,
would be ineffective or even counterproductive. The
pump speed should be adapted to the physical activity,
either by an automatic control that detects exercise and re-
sponds accordingly (such as occurs with rate-responsive
pacemakers) by increasing the pump speed or using a sys-
tem that allows manual changes of the pump speed.
In a recent study, a CF-LVAD was used in patients with
restrictive and hypertrophic cardiomyopathy,28 demonstrat-
ing the technical feasibility of the implantation procedure
and showing no difference in mortality compared with pa-
tients with dilated or ischemic cardiomyopathy treated
with CF-LVAD. Although the patients included in the study
by Topilsky and colleagues28 presented with an ejection
fraction ranging from 20% to 36%, and thus lower than
the ejection fraction considered in the present study, inter-
esting comparisons could be done. Similar to the present re-
sults, the data from Topilsky and colleagues28 showed that
CF-LVAD led to a reduction in pulmonary pressures and
right ventricular systolic pressure. Of the 8 patients initially
with NYHA class IIIb or IV, 7 improved their functional
class, showing better tolerance to physical activity, just as
our simulation studies also suggested. From a clinical view-
point, Topilsky and colleagues28 concluded that patients
with restrictive and hypertrophic cardiomyopathy might
benefit from CF-LVAD therapy but would require a more
careful pump and fluid balance management and careful
right heart monitoring. Accordingly, the simulation results
also suggested that, especially at rest, suction could easily
occur and that algorithms for the robust detection and pre-
vention of suction would be necessary to avoid its occur-
rence. Suction might occur if the ventricular chamber
dimensions are nearly normal and the pump flow exceeds
the blood flow supplied by the venous return. Even if a stiffer
ventricular wall would be less prone to suction, just as the
experience during healthy animal tests suggests, suction
could still occur in the atrium or pulmonary veins.
Some additional aspects and limitations of the present
study should be considered.
Obviously, the present study could not address the clini-
cal performances of CF-LVADs in patients with HFNEF but
only the hemodynamic performances. The question of supe-
riority of this method compared with pharmacologic ther-
apy, the noninferiority of the safety profile, and the issues
related to adverse events and improved patient survival re-
main unanswered and were beyond the scope of our study.The Journal of Thoracic and CarTo address these questions and draw adequate conclusions
about the use of CF-LVADs in this population, a randomized
clinical studymust be performed. The results from a first ex-
perience of CF-LVAD application in 8 patients with restric-
tive and hypertrophic cardiomyopathy compared with
dilated and ischemic cardiomyopathy are encouraging,28
but they need to be confirmed in larger trials.
The model used was based on a careful review of the pub-
lished data of patients with HFNEF without CF-LVAD
support.10-13,16,17,19-22 Even if there is some deviation of
the simulation results (eg, for the EDP and pulmonary
capillary wedge pressure/LAP) from the average
published data, the simulation results always remained
within 1 standard deviation of the published data, which
represents natural patient variability (Table 1 and
Figure 3). This deviation does not signify a poor model rep-
resentation of diastolic filling. The ventricular filling im-
pairment was indeed reflected by the relative change in
both EDV and EDP during exercise, with respect to the at
rest condition (with a small volume increase associated
with a considerable pressure increase). This aspect is very
well reproduced by the model (Table 1 and Figure 3), thus
proving an accurate presentation of the key hemodynamics
of HFNEF. We are, therefore, confident that this model is
a valid tool for elucidating the complex hemodynamic inter-
action between ventricular function and mechanical sup-
port. The use of hemodynamic models such as the one we
have proposed have been demonstrated to be very useful
in previous investigations of mechanical assistance and its
interaction with the native heart. For example, in the study
by Morley and colleagues,24 a hemodynamic simulation
was used to investigate partial mechanical support in those
with mild to severe cardiac failure, with the results
confirmed by a subsequent clinical study.25 Another hemo-
dynamic simulation was used to investigate the heart work
during partial unloading and after removal of a CF-LVAD,6
with the results confirmed and further improved by subse-
quent animal experiments.29
The hemodynamic model did not include long-term
adaptation mechanisms, such as the response to the renin-
angiotensin-aldosterone system, the dynamics of endothe-
lial function and arterial stiffness, or the different degrees
of autonomic dysfunction. These mechanisms must be con-
sidered for the investigation of potential neurohormonal and
arterial (reverse) remodeling. However, the present study
focused only on short-term hemodynamic changes due to
mechanical assistance. Finally, the numeric model was val-
idated against the data from patients with HFNEF that did
not include a CF-LVAD. Therefore, the extrapolation per-
formed by considering the CF-LVADs in the HFNEF model
must undergo experimental in vivo and clinical validation.
Nevertheless, the hemodynamic trends predicted by our
simulation showed patterns similar to those reported by
Topilsky and colleagues.28diovascular Surgery c Volume 145, Number 5 1357
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The results of the present simulation study suggest that
considerable hemodynamic benefits can be achieved with
CF-LVAD use in patients with HFNEF. LV pump support
can unload the pulmonary circulation, especially during
physical activity, thus potentially alleviating the symptoms
and the marked exercise intolerance typical for patients
with HFNEF and, finally, leading to an improved quality
of life. However, a constant speed strategy, such as is cur-
rently used for systolic heart failure assistance, is not
advisable in those with HFNEF because of either an in-
creased risk of suction at rest (if the speed is too high) or in-
effective pulmonary unloading during exercise (if the speed
is too low).References
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